The prognostic value of chromosome studies in patients with the preleukemic syndrome (hemopoietic dysplasia)

Robert L. Anderson, Grover C. Bagby

    Research output: Contribution to journalArticle

    64 Citations (Scopus)

    Abstract

    Banded chromosome studies obtained at the time of diagnosis from 42 patients with the preleukemic syndrome had clonal abnormalities in fifteen. Using Kaplan-Meier product limit survival analysis, it was found that patients with chromosome abnormalities developed acute leukemia more frequently than those without (p <0.05). However, we noted that in a subset of patients with complex abnormalities and in a subset previously exposed to alkylating agents, almost all developed leukemia. When either subset was excluded from the larger group analysis there were no differences in leukemia-free survival between cytogenetically abnormal and normal groups. Thus, in the prognostic evaluation of our patients with the preleukemic syndrome a chromosome abnormality per se did not predict rapid evolution to acute leukemia. However, almost all preleukemic patients with complex chromosome abnormalities and almost all alkylator-exposed preleukemic patients can be expected to develop overt leukemia within 1 yr.

    Original languageEnglish (US)
    Pages (from-to)175-181
    Number of pages7
    JournalLeukemia Research
    Volume6
    Issue number2
    DOIs
    StatePublished - 1982

    Fingerprint

    Chromosomes
    Leukemia
    Chromosome Aberrations
    Alkylating Agents
    Survival Analysis
    Survival

    ASJC Scopus subject areas

    • Cancer Research
    • Hematology
    • Oncology

    Cite this

    The prognostic value of chromosome studies in patients with the preleukemic syndrome (hemopoietic dysplasia). / Anderson, Robert L.; Bagby, Grover C.

    In: Leukemia Research, Vol. 6, No. 2, 1982, p. 175-181.

    Research output: Contribution to journalArticle

    @article{08a5b3407d78478393bcbe5ea6fc1ab4,
    title = "The prognostic value of chromosome studies in patients with the preleukemic syndrome (hemopoietic dysplasia)",
    abstract = "Banded chromosome studies obtained at the time of diagnosis from 42 patients with the preleukemic syndrome had clonal abnormalities in fifteen. Using Kaplan-Meier product limit survival analysis, it was found that patients with chromosome abnormalities developed acute leukemia more frequently than those without (p <0.05). However, we noted that in a subset of patients with complex abnormalities and in a subset previously exposed to alkylating agents, almost all developed leukemia. When either subset was excluded from the larger group analysis there were no differences in leukemia-free survival between cytogenetically abnormal and normal groups. Thus, in the prognostic evaluation of our patients with the preleukemic syndrome a chromosome abnormality per se did not predict rapid evolution to acute leukemia. However, almost all preleukemic patients with complex chromosome abnormalities and almost all alkylator-exposed preleukemic patients can be expected to develop overt leukemia within 1 yr.",
    author = "Anderson, {Robert L.} and Bagby, {Grover C.}",
    year = "1982",
    doi = "10.1016/0145-2126(82)90023-6",
    language = "English (US)",
    volume = "6",
    pages = "175--181",
    journal = "Leukemia Research",
    issn = "0145-2126",
    publisher = "Elsevier Limited",
    number = "2",

    }

    TY - JOUR

    T1 - The prognostic value of chromosome studies in patients with the preleukemic syndrome (hemopoietic dysplasia)

    AU - Anderson, Robert L.

    AU - Bagby, Grover C.

    PY - 1982

    Y1 - 1982

    N2 - Banded chromosome studies obtained at the time of diagnosis from 42 patients with the preleukemic syndrome had clonal abnormalities in fifteen. Using Kaplan-Meier product limit survival analysis, it was found that patients with chromosome abnormalities developed acute leukemia more frequently than those without (p <0.05). However, we noted that in a subset of patients with complex abnormalities and in a subset previously exposed to alkylating agents, almost all developed leukemia. When either subset was excluded from the larger group analysis there were no differences in leukemia-free survival between cytogenetically abnormal and normal groups. Thus, in the prognostic evaluation of our patients with the preleukemic syndrome a chromosome abnormality per se did not predict rapid evolution to acute leukemia. However, almost all preleukemic patients with complex chromosome abnormalities and almost all alkylator-exposed preleukemic patients can be expected to develop overt leukemia within 1 yr.

    AB - Banded chromosome studies obtained at the time of diagnosis from 42 patients with the preleukemic syndrome had clonal abnormalities in fifteen. Using Kaplan-Meier product limit survival analysis, it was found that patients with chromosome abnormalities developed acute leukemia more frequently than those without (p <0.05). However, we noted that in a subset of patients with complex abnormalities and in a subset previously exposed to alkylating agents, almost all developed leukemia. When either subset was excluded from the larger group analysis there were no differences in leukemia-free survival between cytogenetically abnormal and normal groups. Thus, in the prognostic evaluation of our patients with the preleukemic syndrome a chromosome abnormality per se did not predict rapid evolution to acute leukemia. However, almost all preleukemic patients with complex chromosome abnormalities and almost all alkylator-exposed preleukemic patients can be expected to develop overt leukemia within 1 yr.

    UR - http://www.scopus.com/inward/record.url?scp=0020035059&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0020035059&partnerID=8YFLogxK

    U2 - 10.1016/0145-2126(82)90023-6

    DO - 10.1016/0145-2126(82)90023-6

    M3 - Article

    C2 - 7186085

    AN - SCOPUS:0020035059

    VL - 6

    SP - 175

    EP - 181

    JO - Leukemia Research

    JF - Leukemia Research

    SN - 0145-2126

    IS - 2

    ER -